Research

Cancer and neurodegenerative diseases are a major social challenge. The World Health Organization predicts a steady increase in these diseases, which threaten to become the most common causes of mortality in industrialized countries. Imaging procedures are already used for most diagnostic purposes. About every second cancer patient is treated with radiotherapy during the course of the disease. For this reason, there is a pressing need for research and development in the fields of diagnostics and therapy in order to conduct fundamental research for new applications and to quickly translate new scientific solutions into clinical applications for the benefit of patients.

The LOEWE Research Cluster ADMIT therefore aims to combine new imaging and computer-aided procedures with advanced therapeutic strategies in order to enable an early diagnosis and successful treatment of various forms of cancer and neurodegenerative diseases. The core idea of ADMIT is that the development of new medical-physical methods can improve image-guided therapy and provide new insights. Primarily in the fields of radiology, oncology and neurology, the synergetic areas of data processing, imaging and therapy are to be integrated and implemented in innovative, scientifically viable approaches.

ADMIT combines the interdisciplinary and complementary expertise of various researchers from the University of Applied Sciences (THM), Philipps University Marburg (UMR) and Justus Liebig University Giessen (JLU). The research group is complemented by clinical and corporate partners as well as by long-standing THM cooperation partners from Harvard University, Yale University, and the University of Pennsylvania.